A 70-year-old former smoker with FEV1 45% predicted and frequent COPD exacerbations (three steroid-treated exacerbations in the past year) remains dyspnoeic on dual LABA/LAMA therapy. According to the 2023 CTS COPD pharmacotherapy guideline, what is the recommended next pharmacologic step?